Express Scripts Holding Co (NASDAQ:ESRX) – Analysts at William Blair raised their FY2018 EPS estimates for Express Scripts in a note issued to investors on Wednesday, October 31st. William Blair analyst J. Kreger now anticipates that the company will post earnings of $9.08 per share for the year, up from their previous estimate of $9.07. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Express Scripts’ Q3 2019 earnings at $2.51 EPS, FY2019 earnings at $9.74 EPS, FY2020 earnings at $8.05 EPS and FY2021 earnings at $6.96 EPS.
A number of other equities research analysts also recently commented on the stock. BidaskClub upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Tuesday, September 18th. Credit Suisse Group downgraded shares of Express Scripts from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $90.00 to $96.50 in a report on Tuesday, September 18th. ValuEngine upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Monday, September 17th. Royal Bank of Canada lifted their price target on shares of Express Scripts to $94.00 and gave the stock an “outperform” rating in a report on Monday, August 27th. Finally, Mizuho set a $101.00 price target on shares of Express Scripts and gave the stock a “hold” rating in a report on Monday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $89.07.
Shares of NASDAQ ESRX opened at $98.19 on Monday. The stock has a market cap of $54.55 billion, a PE ratio of 13.83, a PEG ratio of 1.22 and a beta of 0.89. Express Scripts has a 12 month low of $59.17 and a 12 month high of $98.98. The company has a quick ratio of 0.65, a current ratio of 0.77 and a debt-to-equity ratio of 0.63.
Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings results on Wednesday, October 31st. The company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.01. The business had revenue of $25.56 billion during the quarter, compared to the consensus estimate of $25.11 billion. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.51 earnings per share.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ESRX. Landaas & Co. WI ADV acquired a new position in Express Scripts during the second quarter valued at approximately $102,000. Kaizen Advisory LLC lifted its position in Express Scripts by 147.6% during the second quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock valued at $104,000 after buying an additional 800 shares in the last quarter. Adviser Investments LLC lifted its position in Express Scripts by 321.9% during the second quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after buying an additional 1,130 shares in the last quarter. TRUE Private Wealth Advisors acquired a new position in Express Scripts during the third quarter valued at approximately $115,000. Finally, Sun Life Financial INC lifted its position in Express Scripts by 758.8% during the second quarter. Sun Life Financial INC now owns 1,520 shares of the company’s stock valued at $117,000 after buying an additional 1,343 shares in the last quarter. 84.20% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Christine Houston sold 12,898 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $85.00, for a total value of $1,096,330.00. Following the sale, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.79% of the stock is currently owned by company insiders.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.